Global Community

Rhythm Pharmaceuticals is a high-growth commercial-stage company targeting orphan neuroendocrine disorders linked to MC4R pathway dysfunction (genetic obesity). Having expanded from one disorder to multiple approved indications, the company has additional opportunities ahead to expand its portfolio.Read more

FreightCar America is coming out of a risky multi-year move to Mexico with a bigger, lower-cost factory that’s now running and starting to simplify its finances. If it keeps taking share in a market that still needs steady railcar replacements, today’s downbeat sentiment could be missing what’s changed.Read more

Lucky Cement Limited (PSX: LUCK) — Fair Value Narrative Proposed fair value: Rs 608 – 668/share (vs. current price ~Rs 458.63 and Simply Wall St's default estimate of Rs 511.80) Thesis Lucky Cement just closed FY2026 (year ended June 30, 2026) with audited consolidated EPS of Rs 60.78, up 15.7% year-on-year — and unlike a lot of "growth" showing up across Pakistani equities this reporting cycle, this one is mostly real.Read more

Novo Nordisk, one of the world’s leading pharmaceutical companies, has a unique and inspiring origin story rooted in personal tragedy and scientific curiosity. The company’s roots date back to the 1920s, when Danish Nobel laureate August Krogh, a renowned physiologist, and his wife Marie, who suffered from type 2 diabetes, traveled to Canada.Read more

If gold prices rise a lot, STLLR Gold could look very different because its large gold resource base becomes far more valuable. The key question is whether investors treat it like a real producer with a value tied to what it can pull out of the ground—or just a pile of ounces on paper.Read more

Initiating Coverage A beneficiary of rising semiconductor complexity – Rigaku’s valuation has re-rated upwards over the past year from a scientific-instrument multiple (low teens PER) to a semi-cap multiple (high 30s to low 40s PER) as investors increasingly recognize the Company’s Semiconductor Process Control Instruments business as the primary growth and earnings driver. We believe Rigaku’s growth upside remains underappreciated as the Company’s FY12/27 medium-term plan (MTP) targets were anchored on a less constructive semiconductor industry environment and outlook.Read more

Denarius Metals is already mining in Colombia and aims to become a real gold-and-silver producer once its new processing plant comes online, which could turn today’s trial shipments into steadier sales. The catch is that it’s juggling several projects and a complicated funding setup, so execution and costs matter as much as the ore grade.Read more

Voyager Technologies looks like a small defense supplier at first glance, but it also has a stake in a planned replacement for the International Space Station that could turn it into a long-term “space landlord.” With government backing and a large cash cushion, the big question is whether this project reaches launch and changes how the company makes money.Read more

Moody’s sits in a regulator-backed gatekeeper role for bond markets, where many big investors effectively need its opinion before they can buy. The twist is that AI may cut Moody’s costs and lift profits without breaking its grip—unless regulators decide ratings matter less.Read more